4.7 Review

Current and Future Development in Lung Cancer Diagnosis

Journal

Publisher

MDPI
DOI: 10.3390/ijms22168661

Keywords

lung cancer; diagnosis; imaging; biomarkers; predictors; body fluids

Funding

  1. MITACS grant [IT22349]
  2. BioMark Diagnostics Inc. (Richmond, BC, Canada)

Ask authors/readers for more resources

Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries, emphasizing the importance of early diagnosis. Current diagnostic methods have limitations and necessitate the search for new biomarkers to improve early detection rates.
Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available